Ocugen (OCGN) Retained Earnings (2014 - 2026)
Ocugen's (OCGN) quarterly Retained Earnings came in at $429.5 million in Q1 2026, up 220.81% YoY from $133.9 million in Q1 2025, and up 704078.69% on a QoQ basis from $61000.0 in Q4 2025.
Analysis
Ocugen (OCGN) Retained Earnings (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 13 years of Retained Earnings data on file, last reported at $429.5 million in Q1 2026.
- Quarterly Retained Earnings rose 220.81% year-over-year to $429.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $429.5 million (up 220.81% YoY) and the FY2025 annual result came in at $61000.0, up 27.08% from the prior year.
- Retained Earnings rose to $429.5 million in Q1 2026, from $61000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $429.5 million in Q1 2026 to a low of -$390.4 million in Q3 2025.
- A 5-year average of -$122.4 million and a median of -$200.7 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2025 — Retained Earnings sank 1697491.3% — and 2026, when it soared 220.81%.
- Tracing OCGN's Retained Earnings over 5 years: stood at -$223.1 million in 2022, then declined by 28.27% to -$286.2 million in 2023, then surged by 100.02% to $48000.0 in 2024, then gained by 27.08% to $61000.0 in 2025, then soared by 704078.69% to $429.5 million in 2026.
- The last three Retained Earnings figures came in at $429.5 million (Q1 2026), $61000.0 (Q4 2025), and -$390.4 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Ocugen | 458.91 Mn | 358.81 Mn | - | -452.12 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -452.12 Mn |
| Mar 31, 2026 | 429.55 Mn |
| Dec 31, 2025 | -408.07 Mn |
| Sep 30, 2025 | 390.76 Mn |
| Jun 30, 2025 | 370.47 Mn |
| Mar 31, 2025 | 368.57 Mn |
| Dec 31, 2024 | 366.94 Mn |
| Sep 30, 2024 | 364.09 Mn |
| Jun 30, 2024 | 327.74 Mn |
| Mar 31, 2024 | 325.80 Mn |
| Dec 31, 2023 | 324.19 Mn |
| Sep 30, 2023 | 322.45 Mn |
| Jun 30, 2023 | 320.18 Mn |
| Mar 31, 2023 | 303.07 Mn |
| Dec 31, 2022 | 294.87 Mn |
| Sep 30, 2022 | 284.23 Mn |
| Jun 30, 2022 | 281.14 Mn |
| Mar 31, 2022 | 278.70 Mn |
| Dec 31, 2021 | 225.54 Mn |
| Sep 30, 2021 | 222.25 Mn |